{"entity":{"id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","aka":[],"tldr":"A phase 3 trial testing KL-A167 in nasopharyngeal carcinoma, active and no longer recruiting.","summary":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT05294172, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting on the registry. Official title: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomised, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. Planned enrolment is 295 participants (actual). The study started in 2022-06-07 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05294172","url":"https://clinicaltrials.gov/study/NCT05294172"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nasopharyngeal","recurrent-metastatic-nasopharyngeal-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["kl-a167"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05294172","phase":"3","setting":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","started":"2022-06-07","startedType":"actual","enrolled":295,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05294172/","neighbours":{"cancer":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"}],"drug":[{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}